The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

Markus Hoffmann, Nadine Krüger, Sebastian Schulz, +12

Cell

Covid-19 PandemicImmunologyAntibody-mediated NeutralizationAntiviral TherapyAntiviral Response +7

Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination

Joana Barros‐Martins, Swantje I. Hammerschmidt, Anne Cossmann, +22

Nature Medicine

Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods

Berislav Bošnjak, Saskia C. Stein, Stefanie Willenzon, +19

Cellular and Molecular Immunology

SARS-CoV-2 BA.2.86 enters lung cells and evades neutralizing antibodies with high efficiency

Lu Zhang, Amy Kempf, Inga Nehlmeier, +15

Cell

Sars-cov-2 Ba.2.86 EntersHigh EfficiencyViral PathogenesisImmunologyHumoral Response +4

Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals

Georg M. N. Behrens, Anne Cossmann, Metodi V. Stankov, +4

Infection

Cellular and humoral immunogenicity of a SARS-CoV-2 mRNA vaccine in patients on haemodialysis

Monika Strengert, Matthias Becker, Gema Morillas Ramos, +16

EBioMedicine

The Omicron variant is highly resistant against antibody-mediated neutralization – implications for control of the COVID-19 pandemic

Markus Hoffmann, Nadine Krüger, Sebastian Schulz, +12

VaccinationVaccine TargetDelta SpikeImmunologyAntiviral Response +12

Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy

Nils Jedicke, Metodi V. Stankov, Anne Cossmann, +5

HIV Medicine

SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies

Prerna Arora, Lu Zhang, Nadine Krüger, +12

Cell Host & Microbe

Differential NeutralizationComparable Cell EntryViral PathogenesisImmunologyAntiviral Response +5

Strategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals

Georg M. N. Behrens, Anne Cossmann, Metodi V. Stankov, +19

Infectious Diseases and Therapy